Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 29 Aug - Newspaper Advertisement regarding 44th Annual General Meeting (AGM) of the Company
Source: Bse
Mangalam Organics Limited (MANORG)
Small CapIndustrials stocks · Small cap · NSE
Mangalam Organics Limited operates in Chemicals, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result28 Jul, 10:58 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Industrials P/E 26.2 (n=537)
Technical timing lens
Trend score and candlestick chart
51NeutralSMA20 -7.8% / mo · MACD +
Stock trend: 55
Sector RS: 46
Sector 3M: -7.1% vs Nifty 500 -5.6%
Industrials FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
MANORGD candles · FIT view+6.6%Latest close ₹485.65 on 2026-10-21
Bar
+0.1%
RSI
63
MACD hist
6.55
52W pos
46%
2026-10-21O ₹485.40H ₹510.00L ₹451.65C ₹485.65Vol 17,102 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
MANORGNifty India ManufacturingNifty 500
- MANORG
- -15.0%
- Nifty 500
- -6.5%
- Nifty India Manufacturing
- -7.7%
- Vs Nifty 500
- -8.5 pp
Chart stats
21 Oct 2026- From 52W high
- -23.5%
- 52W range position
- 46%
- ATR (14)
- 5.1%
- Volume vs 20D
- 2.99x
- Avg traded value
- ₹0.3 Cr
- 20D price channel
- ₹406 - ₹510
₹635
₹356.3 - ₹635
₹24.6
Latest completed session
20-session average
44.5% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · OVERVALUED24
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad2
Revenue +22.2% · PAT -40.6% YoY
Technical
Neutral51
Price trend and sector-relative-strength timing.
Valuation
Legacy model-773.4%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence64
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 2/100PAT -41% YoY · margin compression · Rev +22% YoY · +17% QoQ
Filed 28 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹179.1 Cr | +22.2% | +16.6% |
| EBITDA | ₹22.2 Cr | +2.7% | -52.4% |
| Operating margin | 12.4% | -235 bps | -1797 bps |
| PAT | ₹7.3 Cr | -40.6% | +21.6% |
| PAT margin | 4.1% | -429 bps | +17 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 15.80
- P/B
- 1.16
- EV/EBITDA
- 6.23
- Market Cap
- 370.00Cr
Profitability
- ROE
- 8.44%
- ROCE
- 9.90%
- ROA
- 2.84%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 12.00%
- EPS 5Y
- -21.00%
- Revenue 3Y
- 7.00%
- EPS 3Y
- 43.00%
Balance Sheet
- Debt/Equity
- 1.13
- Interest Coverage
- 2.93×
- Altman Z
- 2.55
- Book Value
- 372.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 3/5
- OCF
- 1.00 Cr
- EPS TTM
- 24.28
Shareholding
- Promoter Hold
- 58.64%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 28%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 179+16.6% vs prev
Net Profit
₹ CrLatest: 7.3+21.6% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 63. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~8.5% over last month) — short-term momentum negative.
- RSI(14) at 63 — rising, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- 24% off 52W high · 36% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
60
RS percentile
Stage 3 Topping
1M return
+4.6%
3M return
-15.0%
6M return
+6.1%
1Y return
-6.8%
RS 1D
+3
RS 20D
+16
Sector rank
#2
Industry rank
#6
Stage evidence
- 21.7% below the 52-week closing high after prior strength.
- The 30-week proxy has stalled (+1.0% over 20 sessions).
- Price has not yet confirmed a full Stage 4 downtrend.
50-DMA
price above
200-DMA
price above
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 95.01+1.53%
RS vs Nifty 50095
Valuation & peers
U-Score 24 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 24 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation7/30
Growth6/25
Quality2/20
Balance Sheet6/15
Cash Flow3/10
Piotroski
6/9 (+3)
Penalties
-3
Raw sum
24
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
24/100 · legacy band OVERVALUED
Positive drivers
- Balance sheet contributes 6/15 to the score.
- Cash flow contributes 3/10 to the score.
- Growth contributes 6/25 to the score.
Main drags
- Penalty bucket subtracts 3 points.
- Fair-value margin of safety is negative at -773.4%.
- Quality is weaker at 2/20; verify the latest quarterly trend.
Sector valuation model
Cyclical valuation: normalized earnings, not just trailing PE
Cyclical companies can look cheapest near peak profits, so IndiaPulse flags value-trap risk separately.
Primary lens
Mid-cycle PE/EV/EBITDA using multi-year average margins or earnings.
Secondary checks
Current margin versus 5-year average, balance sheet strength, commodity cycle.
Main risk check
A low trailing PE may mean peak-cycle earnings, not true cheapness.
PE
15.8
PB
1.2
EV/EBITDA
6.2
ROE
8.4%
ROCE
9.9%
FCF Yield
—
Debt/Equity
1.1
MoS
-773.4%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE. Debt/equity is 1.1, so downturn resilience matters.
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
24
Previous: 24
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-773.4%
Previous: -768.1%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
29
29
29
31
31
31
29
29
29
29
24
24
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹450.8
-7.7% MoS
Growth-justified P/E
2.3
Growth-justified Value
₹55.6
-773.4% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Industrials — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
UNIENTER
Small
Uniphos Enterprises Limited
Specialty Chemicals
match 161
33
29.6
0.8%
-405%
WATCHLIST
BLACKROSE
Small
Black Rose Inds. Limited
Specialty Chemicals
match 158
40
19.5
13.6%
-225%
WATCHLIST
SADHNANIQ
Small
Sadhana Nitrochem Limited
Specialty Chemicals
match 156
18
—
-23.5%
—
OVERVALUED
IVP
Small
IVP Limited
Specialty Chemicals
match 156
73
7.3
12.8%
+82%
UNDERVALUED
TRANSPEK
Small
Transpek Industry Limited
Specialty Chemicals
match 156
55
18.8
6.1%
+49%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Mangalam Organics Limited operates in Chemicals, within the Industrials sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
64Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 42nd percentile of the scored universe and 40th percentile within Industrials. Main check: balance sheet trust is weak at 53/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
56 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
42nd percentile
overall median 67 · Industrials: 40th pctile, median 68 · Small: 47th pctile, median 66
Evidence depth
Financial-only
56 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
55
watch · profit to cash conversion
Balance sheet
53
watch · leverage and solvency
Discipline
68
acceptable · capital discipline
Results
62
acceptable · quarterly consistency
Trust positives
- ▸Promoter holding is 58.6%.
- ▸Promoter pledge is zero.
- ▸4/4 latest quarters had positive YoY revenue growth.
- ▸3/4 latest quarters had positive YoY PAT growth.
Trust risks
- ▸Debt/equity is 1.13.
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
- ▸OPM spread across recent quarters is 30.2%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Mangalam Organics Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Aug - Newspaper Clippings for the notice sent to the shareholders for transfer of shares to the Investor Education and Protection Fund
Source: Bse
Credit rating
Announcement under Regulation 30 (LODR)-Credit Rating 1 Jul - CRISIL upgraded Mangalam Organics’ Rs.397 crore bank facilities to BBB+/Stable; subsidiary got BBB+/Stable on Rs.80 crore.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.